Giacomo De Luca

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Giulio Cavalli, Giacomo De Luca, Corrado Campochiaro et al. · The Lancet Rheumatology · 2020 · 991 citations · Full text

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

Corrado Campochiaro, Emanuel Della‐Torre, Giulio Cavalli et al. · European Journal of Internal Medicine · 2020 · 408 citations · Full text

Long Covid, Covid-19 Pandemic, Severe Covid-19 Patients +6

Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors

Marco Ripa, Laura Galli, Andrea Poli et al. · Clinical Microbiology and Infection · 2020 · 383 citations · Full text

Infectious Disease Epidemiology, Predictive Factors, Healthcare-associated Infection +12

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

François-Xavier Lescure, Hitoshi Honda, Robert Fowler et al. · The Lancet Respiratory Medicine · 2021 · 246 citations · Full text

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study

Giacomo De Luca, Giulio Cavalli, Corrado Campochiaro et al. · The Lancet Rheumatology · 2020 · 205 citations · Full text

Inflammation, Translational Medicine, Medicine +9